USPTO Examiner WHITE DAWANNA SHAR DAY - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19237465MIRDAMETINIB TREATMENTJune 2025March 2026Abandon910NoNo
19030481MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTSJanuary 2025June 2025Abandon510NoNo
18977389METHODS OF TREATING GRADE 3 ASTROCYTOMADecember 2024January 2026Allow1330YesNo
18920212SMALL MOLECULE INHIBITORS OF KRAS PROTEINSOctober 2024March 2025Allow501NoNo
18912328MIRDAMETINIB TREATMENTOctober 2024February 2026Abandon1620NoNo
18912341MIRDAMETINIB TREATMENTOctober 2024February 2026Abandon1620NoNo
18634899APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVEApril 2024October 2025Allow1810NoNo
18616625Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic VirusMarch 2024February 2026Abandon2240YesNo
18492718THERAPEUTIC FORMULATIONS AND USES THEREOFOctober 2023October 2025Abandon2440NoNo
18256831BORONIC ACID COMPOUNDSJune 2023November 2025Allow2900NoNo
18314445ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCERMay 2023March 2024Allow1110NoNo
18311708SALTS AND POLYMORPHS OF CERTAIN MCL-1 INHIBITORSMay 2023July 2024Allow1510NoNo
18034122NOVEL COMPOUNDSApril 2023March 2026Allow3501NoNo
18034367HIGH ACTIVITY HPK1 KINASE INHIBITORApril 2023March 2026Abandon3401NoNo
18303226GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEMApril 2023November 2024Allow1911YesNo
18187124DIHYDROCHROMENE DERIVATIVESMarch 2023June 2025Allow2701YesNo
18120890COMPOSITIONS AND METHODS FOR TREATING SKIN AND NEUROPATHIC CONDITIONS AND DISORDERSMarch 2023July 2025Abandon2900NoNo
18041223Heterocycle CDK Inhibitors And Their Use ThereofFebruary 2023January 2026Abandon3501NoNo
18040861CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTSFebruary 2023September 2025Allow3100NoNo
18019891PIN1 INHIBITORS AND USES THEREOFFebruary 2023February 2026Abandon3601NoNo
18161678PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOFJanuary 2023May 2025Allow2831YesNo
18068902PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTSDecember 2022May 2024Allow1711NoNo
18067408Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic VirusDecember 2022February 2026Abandon3810NoNo
18060053ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCERNovember 2022March 2024Abandon1610NoNo
18052851LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBLNovember 2022August 2024Allow2210NoNo
17978469COMPOUNDS FOR METHODS FOR PROMOTING FEMALE REPRODUCTIVE HEALTH THROUGH MEDIATION OF RENIN ANGIOTENSIN FUNCTIONNovember 2022July 2024Abandon2001NoNo
17997531AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORSOctober 2022August 2025Allow3400NoNo
18049892AMANTADINE HYDROCHLORIDE FOR THE TREATMENT OF TRAUMATIC BRAIN INJURYOctober 2022July 2025Allow3330YesNo
17920085CO-CRYSTAL OF GABAPENTIN, KETOPROFEN AND LYSINE, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USEOctober 2022November 2025Allow3710NoNo
18047960SOLID PHARMACEUTICAL TABLETOctober 2022May 2024Abandon1910NoNo
17955425CANNABINOID-CONTAINING FORMULATIONS FOR PARKINSONIAN MOVEMENT DISORDERSSeptember 2022June 2024Abandon2111NoNo
179142455-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCERSeptember 2022January 2026Allow4011YesNo
17932509PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOFSeptember 2022March 2026Abandon4221NoYes
17895443FENFLURAMINE FOR TREATMENT OF DEMYELINATING DISEASES AND CONDITIONSAugust 2022May 2025Allow3340NoNo
17886990Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver ConditionsAugust 2022February 2026Allow4250NoNo
17759713USE OF POZIOTINIB FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONSJuly 2022January 2026Allow4211NoNo
17795751PRODRUGS USEFUL IN ADOPTIVE CELL THERAPYJuly 2022January 2026Abandon4110NoNo
17783364Crystalline Form of a 7H-Benzo[7]Annulene-2-Carboxylic Acid DerivativeJune 2022October 2025Allow4110NoNo
17770708METTL3 MODULATORSApril 2022November 2025Abandon4301NoNo
17716273BISDIAZABICYCLO COMPOUND FOR TREATING AND/OR PREVENTING HEPATITIS VIRUS-RELATED DISEASES OR DISORDERSApril 2022October 2024Abandon3020NoNo
17715463CHEMICAL COMPOUNDSApril 2022December 2025Allow4410NoNo
17762683MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTSMarch 2022November 2025Allow4411YesNo
17633249NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTI-FIBROSIS COMPOSITION COMPRISING SAMEFebruary 2022September 2025Abandon4301NoNo
17631955PRODRUGS AND FORMULATIONS THEREOFFebruary 2022November 2025Abandon4611NoNo
17581010SELECTIVE GRP94 INHIBITORS AND USES THEREOFJanuary 2022December 2025Allow4721NoNo
17625982NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASEJanuary 2022September 2025Allow4520NoNo
17625103ALKYNE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOFJanuary 2022August 2025Allow4311NoNo
17624297ESTROGEN-RELATED RECEPTOR ALPHA MODULATORSDecember 2021September 2025Allow4511NoNo
17564549COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIESDecember 2021January 2026Abandon4811NoNo
17556147METHODS OF TREATMENT USING PHENYL INDOLE ALLOSTERIC INHIBITORS OF P97 ATPASEDecember 2021October 2025Allow4611NoNo
17620188Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide DerivativesDecember 2021May 2025Allow4110YesNo
17620242EGFR INHIBITORS FOR THE TREATMENT OF CANCERDecember 2021October 2025Allow4611NoNo
17619359NEW TRICYCLIC 5-HT2 ANTAGONISTSDecember 2021May 2025Abandon4110NoNo
17525473HYBRID CURCUMIN CONJUGATES AND METHODS OF USE THEREOFNovember 2021December 2025Abandon4912NoNo
17603961FUSED ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORSOctober 2021November 2024Allow3700NoNo
17602989COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISMOctober 2021June 2025Allow4411NoNo
17441085WEE1 INHIBITOR AND PREPARATION AND USE THEREOFSeptember 2021March 2025Abandon4201NoNo
17447795SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USESeptember 2021April 2025Abandon4301NoNo
17437780CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOFSeptember 2021June 2025Allow4511NoNo
17310824MACROCYCLIC COMPOUNDSAugust 2021March 2025Abandon4201NoNo
17402229PROSTATE FUNCTION SUPPORT FORMULAAugust 2021March 2025Abandon4410NoNo
17310610FGFR INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFORAugust 2021May 2025Allow4521NoNo
17430373CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOFAugust 2021February 2025Allow4210NoNo
17428094USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD)August 2021March 2025Abandon4310NoNo
17428090USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHYAugust 2021March 2025Abandon4410NoNo
17426804HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTIONJuly 2021March 2025Allow4311YesNo
17424690NEW CRYSTALLINE FORMS OF A SUCCINATE SALT OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE -6-CARBOXYLIC ACID DIMETHYLAMIDEJuly 2021May 2025Allow4520NoNo
17373006COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PULMONARY HYPERTENSIONJuly 2021June 2025Abandon4710NoNo
17421428HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOFJuly 2021March 2025Allow4411NoNo
17370231COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASESJuly 2021August 2025Allow4921YesNo
17420335TOPICAL FORMULATIONS HAVING CANNABINOIDJuly 2021December 2024Abandon4110NoNo
17417983THIENOPYRIDINONE COMPOUNDSJune 2021May 2025Allow4611NoNo
17417805COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1June 2021August 2025Abandon5001YesNo
17417309METHOD FOR TREATING DRUG OR ALCOHOL DEPENDENCYJune 2021February 2026Allow5621NoNo
17414655USE OF SULCONAZOLE AS A FURIN INHIBITORJune 2021March 2025Abandon4511NoNo
17414579COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTIONJune 2021November 2024Abandon4101NoNo
17277921CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological ConditionsJune 2021August 2025Abandon5320YesNo
17345557MUSCARINIC RECEPTOR AGONISTSJune 2021September 2024Allow3910NoNo
17312669ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOFJune 2021October 2024Allow4110YesNo
17311930DISUBSTITUTED ALKYNE DERIVATIVESJune 2021February 2025Allow4411YesNo
17311388ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ALCOHOL COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAMEJune 2021November 2025Allow5321YesNo
17299760THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCERJune 2021December 2024Abandon4311NoNo
17298225CARBORANE-BASED HISTONE DEACETYLASE (HDAC) INHIBITORSMay 2021January 2025Abandon4411NoNo
17296460EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUGMay 2021April 2025Allow4721YesNo
17296355INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFORMay 2021October 2024Abandon4001NoNo
17295497NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORSMay 2021December 2024Allow4320NoNo
17325193Difluoro Phenyl Amide RIP1 InhibitorMay 2021July 2024Allow3820NoNo
17294225ERK INHIBITORS AND USES THEREOFMay 2021June 2025Allow4911NoNo
17293255ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICSMay 2021March 2025Allow4621NoNo
17292571SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USEMay 2021March 2025Allow4721NoNo
172919945-[6-[[3-(4,5,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDIN-1-YL)AZETIDIN-1-YL]METHYL]MORPHOLIN-4-YL]QUINOLINE-8-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS TLR7-9 ANTAGONISTS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUSMay 2021April 2024Allow3500NoNo
17290992COMPOSITION FOR INCREASING RETENTION OF CAROTENOID IN BLOODMay 2021September 2024Abandon4110NoNo
17290257APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVEApril 2021March 2025Allow4730NoNo
17289125Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)April 2021July 2024Allow3921NoNo
17238273MACROPINOCYTOSIS IN CANCERApril 2021September 2024Abandon4001NoNo
17272998AMELIORATING AGENT FOR OBESITY-RELATED METABOLIC DISEASEApril 2021December 2025Abandon5830YesNo
17286967COMPOSITION FOR PREVENTING OR TREATING SJOGREN'S SYNDROMEApril 2021August 2024Abandon4010NoNo
17286936HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEApril 2021May 2024Allow3710YesNo
17285622QUINONE REDUCTASE 2 INHIBITOR COMPOUNDS AND USES THEREOFApril 2021February 2025Allow4621YesNo
17285776PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDSApril 2021June 2024Allow3810NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WHITE, DAWANNA SHAR-DAY.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
1
(25.0%)
Not Allowed After Appeal Filing
3
(75.0%)
Filing Benefit Percentile
33.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WHITE, DAWANNA SHAR-DAY - Prosecution Strategy Guide

Executive Summary

Examiner WHITE, DAWANNA SHAR-DAY works in Art Unit 1627 and has examined 78 patent applications in our dataset. With an allowance rate of 59.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.

Allowance Patterns

Examiner WHITE, DAWANNA SHAR-DAY's allowance rate of 59.0% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WHITE, DAWANNA SHAR-DAY receive 1.68 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WHITE, DAWANNA SHAR-DAY is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +36.6% benefit to allowance rate for applications examined by WHITE, DAWANNA SHAR-DAY. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.8% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.3% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.